METTL14-mediated m6A modification of ZFP14 inhibits clear cell renal cell carcinoma progression via promoting STAT3 ubiquitination

Zhuonan Liu; Tianshui Sun; Zhe Zhang; Chiyuan Piao; Chuize Kong; Xiaotong Zhang

doi:10.1002/ctm2.70232

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (2) : e70232 DOI: 10.1002/ctm2.70232

RESEARCH ARTICLE

METTL14-mediated m6A modification of ZFP14 inhibits clear cell renal cell carcinoma progression via promoting STAT3 ubiquitination

Author information +

History +

PDF

Abstract

	•ZFP14 under-expression is associated with ccRCC tumourigenesis and progression.
	•METTL14-mediated m6A enhances ZFP14 mRNA stability and expression with IGF2BP2 as the reader in ccRCC.
	•ZFP14 promotes the degradation of STAT3 by enhancing its K48-linked ubiquitination, inhibiting ccRCC progression.

Keywords

ccRCC / m6A / METTL14 / STAT3 / ubiquitination / ZFP14

Cite this article

Download citation ▾

Zhuonan Liu,Tianshui Sun,Zhe Zhang,Chiyuan Piao,Chuize Kong,Xiaotong Zhang. METTL14-mediated m6A modification of ZFP14 inhibits clear cell renal cell carcinoma progression via promoting STAT3 ubiquitination. Clinical and Translational Medicine, 2025, 15(2): e70232 DOI:10.1002/ctm2.70232

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.